ZIMMER BIOMET HOLDINGS, INC.
About ZIMMER BIOMET HOLDINGS, INC.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $8.2B
- Net income
- $705.1M
- Total assets
- $23.1B
- Market cap
- $16.9B
- Gross margin
- 69.7%
- Operating margin
- 13.3%
- Net margin
- 8.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $8.2B
- Cost of revenue
- $2.5B
- Gross profit
- $5.7B
- Operating expenses
- $4.6B
- Operating income
- $1.1B
- Income tax
- $125.7M
- Net income
- $705.1M
- EPS (basic)
- $3.56
- EPS (diluted)
- $3.55
Balance sheet
- Total assets
- $23.1B
- Current assets
- $5.1B
- Total liabilities
- $10.4B
- Current liabilities
- $2.6B
- Shareholders’ equity
- $12.7B
Cash flow
- Operating cash flow
- $1.7B
- Investing cash flow
- -$2.0B
- Financing cash flow
- $326.0M
- Net cash flow
- $47.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $16.9B
- P/E ratio
- 24.6
- EPS (diluted)
- $3.55
- Dividend yield
- 1.1%
- Shares outstanding
- 193.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 7, 2001
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $705.1M in FY2025.
- Revenue grew 5% from FY2021 to FY2025.
- Gross margin of 69.7%, net margin 8.6%.
- Trading 19% below its 52-week high.
- Pays a dividend yielding about 1.1% annually.
- Valued at a price-to-earnings (P/E) ratio of 24.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review ZIMMER BIOMET HOLDINGS, INC..
Write a review
News about ZIMMER BIOMET HOLDINGS, INC.
News & sentiment via Polygon.io
